1. U.S. Food and Drug Administration. Information on Erythropoiesis‐Stimulating Agents (ESA) Epoetin alfa (Marketed as Procrit Epogen) Darbepoetin Alfa (Marketed as Aranesp). July 9 2015. Available from:https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109375.htm(accessed October 22 2019).
2. KDIGO clinical practice guideline for anemia in chronic kidney disease;Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group;Kidney Int Suppl,2012
3. Department of Health and Human Services Centers for Medicare and Medicaid Services. 42 CFR parts 410 413 and 414; Medicare program; end‐stage renal disease prospective payment system; final rule and proposed rule.Federal Register2010 August 12;75. Available from:https://www.gpo.gov/fdsys/pkg/FR-2010-08-12/pdf/2010-18466.pdf(accessed October 22 2019).
4. GilbertsonDT CollinsAJ FoleyR. Transition in service utilization: vascular access injectables hemoglobin levels and transfusions. Presented in Special Session: "USRDS: Assessment of the new bundled dialysis payment system and overview of the ESRD program" at the American Society of Nephrology Kidney Week Annual Meeting November 1 2012. Available from:http://www.usrds.org/2012/pres/ASN2H/Gilbertson_USRDS_2-hour_Full.pdf. (accessed October 22 2019).
5. Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*